Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP, discusses updated data from the phase 1a/1b trial of zongertinib in patients with HER2 aberration-positive solid tumors. In this video, she reports data from phase 1b, the ongoing dose expansion phase, which includes patients with HER2 mutation–positive NSCLC and focuses on nursing considerations for managing adverse events.
Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP
Advanced Practice Registered Nurse
Department of Investigational Cancer Therapeutics
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Sponsored by
